Barr Laboratories, Inc.
Records under this name other than the patents Barr Laboratories, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Back to Barr Laboratories, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,406,154 | Transdermal Dosage Form Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,010,543 | Transdermal Dosage Form Formerly held Lapsed on the fee record Ended Jul 3, 2026 · Medium confidence | Lapsed on the fee record | Ended Jul 3, 2026 | Medium confidence |
| US 7,320,969 | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology Formerly held Term ended Term ended Jan 30, 2024 · From the USPTO record | Term ended | Term ended Jan 30, 2024 | From the USPTO record |
| US 7,858,605 | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology Formerly held Lapsed on the fee record Ended Dec 28, 2022 · From the USPTO record | Lapsed on the fee record | Ended Dec 28, 2022 | From the USPTO record |
| US 8,680,084 | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology Formerly held Lapsed on the fee record Ended Mar 25, 2022 · From the USPTO record | Lapsed on the fee record | Ended Mar 25, 2022 | From the USPTO record |
| US 7,615,545 | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology Formerly held Lapsed on the fee record Ended Nov 10, 2021 · From the USPTO record | Lapsed on the fee record | Ended Nov 10, 2021 | From the USPTO record |
| US 6,660,726 | Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same Formerly held Term ended Term ended Mar 8, 2021 · From the USPTO record | Term ended | Term ended Mar 8, 2021 | From the USPTO record |
| US 6,844,334 | (3) and (6) substitued estrogenic compounds Formerly held Term ended Term ended Mar 8, 2021 · From the USPTO record | Term ended | Term ended Mar 8, 2021 | From the USPTO record |
| US 8,338,396 | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology Formerly held Lapsed on the fee record Ended Dec 25, 2020 · From the USPTO record | Lapsed on the fee record | Ended Dec 25, 2020 | From the USPTO record |
| US 7,459,445 | Estrogenic compounds and topical pharmaceutical formulations of the same Formerly held Lapsed on the fee record Ended Dec 2, 2020 · From the USPTO record | Lapsed on the fee record | Ended Dec 2, 2020 | From the USPTO record |